Advertisement
Advertisement

ANIP

ANIP logo

ANI Pharmaceuticals Inc

54.78
USD
-1.06
-1.89%
Dec 18, 14:49 UTC -5
Open

ANI Pharmaceuticals Inc Profile

About

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.

Info & Links

CEO

Nikhil Lalwani

Headquarters

210 Main Street West
Baudette, MN 56623, UNITED STATES

Industry

Biotechnology

Sector

Health Technology

Website

www.anipharmaceuticals.com

Auditor

EisnerAmper LLP

Share holders

270

Employees

642

ANI Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

1.15B

Enterprise Value

1.63B

Enterprise Value/EBITDA(ttm)

21.69

Price to Earnings Ratio(ttm)

16.21

Price to Sales(ttm)

2.14

Price to Book(mrq)

2.94

Price to Cash(ytd)

8.82

Profitability

Gross Margin(ttm)

59.83%

Operating Margin(ttm)

12.47%

Profit Margin(ttm)

-1.25%

Return on Equity(ttm)

15.87%

Return on Invested Capital(ttm)

-0.06%

Return on Assets(ttm)

6.88%

Income Statement

Revenue(ttm)

555.46M

Revenue Per Share(ttm)

26.41

Gross Profit(ttm)

332.11M

EBITDA(ttm)3

75.24M

Net Income Available to Common(ttm)

-8.72M

Diluted EPS(ttm)

-0.55

Share Statistics

Beta (5Y Monthly)

0.73

52-Week Change

9.40%

S&P 500 52-Week Change

26.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

21.03M

Dividend Yield

0.00%

Float4

18.36M

% Held by Insiders

12.70%

% Held by Institutions

76.05%

Balance Sheet

Total Cash(mrq)

153.31M

Total Cash Per Share(mrq)

7.29

Total Debt(mrq)

625.36M

Total Debt/Equity(mrq)

145.16%

Current Ratio(mrq)

2.74%

Quick Ratio(mrq)

1.97%

Book Value Per Share(mrq)

20.44

Cash Flow

Operating Cash Flow Per Share(ytd)

2.48

Free Cash Flow(ytd)

47.83M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement